Drug development is no easy feat. But even when the intricacies of manufacturing are perfected, there remains the hurdle of getting treatments from production facilities to patients.
BioPharma Dive is taking a trip along the pharmaceutical supply chain to explore these challenges. We'll have a look at foreign API makers and the troubles they've had staying compliant, as well as carriers and the advanced solutions they've adopted to make CAR-T therapies viable. Also on tap is the Drug Supply Chain Security Act and where contract manufacturers are in meeting its deadlines.
-
Top challenges facing drug supply chains
Issues like GMP compliance and cold-chain shipping are just two of the hurdles that must be overcome for medicines to travel from drugmakers to patients. Read More »
-
The Drug Supply Chain Security Act: A progress report
Five years in and one enforcement extension later, pharmaceutical companies still have a long way to go to fulfill the goal of true traceability. Read More »
-
CAR-T ups challenges in pharma supply chain
New technology made shipping the cell therapies viable. Now, stakeholders are pushing for more innovation to meet looming commercial demands. Read More »
-
As India, China drug industries mature, FDA scrutiny an overhang
Rising numbers of warning letters have put production quality in focus, just as both countries turn further toward novel drug R&D. Read More »
-
Phama supply chains could use a tech reboot
While more prosaic than drug R&D, supply chains are increasingly important as the industry moves toward personalized medicine. Read More »